Table 2.
Ongoing clinical trials on the use of statins and renal function
| Study | Estimated enrollment | Statin | Baseline eGFR (mL/minute) | Endpoint |
|---|---|---|---|---|
| PRATO-ACS 2 study44 | 760 | Rosuvastatin 40 mg followed by 20 mg/day versus atorvastatin (80 mg followed by 40 mg/day) | Any, except ESRD or AKI | To compare the nephroprotective effects of high-dose atorvastatin and high-dose rosuvastatin. |
| Anti-inflammatory and renoprotective effect of pretreatment loading dose atorvastatin in CABG61 | 80 | Load of atorvastatin 80 mg + 40 mg | GFR >60 mL/minute | Safety and efficiency study of loading dose of atorvastatin in cardiac surgery. |
| Short-term atorvastatin’s effect on acute kidney injury following cardiac surgery62 | 820 | Atorvastatin 80 mg (load), followed by 40 mg/day | Any, except ESRD | Short-term atorvastatin’s effect on acute kidney injury following cardiac surgery. |
| PRINCIPLE-II study63 | 404 | Pitavastatin 4 mg/day for 7 days before angiography | eGFR ≤60 mL/minute | Preventive effect of pitavastatin on contrast-induced nephropathy in patients with renal dysfunction. |
| SARP study64 | 40 | Atorvastatin 40 mg versus 10 mg | CKD stage 3–4 | To evaluate the comparative effects of low-dose atorvastatin on proteinuria in patients with stage 3 or 4 chronic kidney disease. |
| SCIN study65 | 200 | Load of atorvastatin 80 mg + 40 mg | Creatinine >1.3 mg/dL or GFR <60 mL/minute | To determine if statin therapy plus intravenous normal saline, in patients with CKD undergoing angiography, is superior to placebo plus intravenous normal saline therapy in the prevention of CIN. |
Abbreviations: eGFR, estimated glomerular filtration rate; PRATO-ACS 2, Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury; ESRD, end-stage renal disease; AKI, acute kidney injury; CABG, coronary artery bypass graft; GFR, glomerular filtration rate; PRINCIPLE-II, Preventive Effect of the PRetreatment With pitavastatiN on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndErgoing Coronary Angiography/Intervention; SARP, Study of Atorvastatin Dose Dependent Reduction of Proteinuria; CKD, chronic kidney disease; SCIN, Efficacy of Statins In Prevention of CIN; CIN, contrast-induced nephropathy.